Prostate cancer is now the most common malignancy and the second leading cause of cancer death in North American males. Androgen antagonists offer a potentially useful treatment for androgen mediated diseases, such as prostate cancer, hirsutism, acne, seborrhea, androgenic alopecia and benign prostatic hyperplasia.
The X-ray data for the crystals of the title compound were collected by graphite-monochromatized Mo Kα radiation at 293 K. No absorption correction was applied. The crystal is not sufficiently stable to X-ray beam and diffracts poorly. The structure was solved by direct methods and refined by fullmatrix least-squares with anisotropic temperature factors for the non-hydrogen atoms. The hydrogen atoms bonded to C atoms were assigned based on the expected bonding geometry. The hydrogen atoms were refined isotropically in the final leastsquares cycles. The software used to prepare material for Table 1 summarizes the crystal and experimental data. The molecular structure is shown in Fig.  1 .
The molecule consists of three six-membered rings and one five-membered ring, all trans fused. For the puckeringparameters values (φ2, θ2 and Q), 9 the six-membered rings A, B and C occur in a distorted envelope ( 1 E), a distorted half chair ( 5 H6) and a chair ( 1 C4) conformations, respectively. Ring D occurs in a distorted half chair conformation. The bond lengths and angles are normal. The stereochemistry of the title compound is as follows: C8-βH is trans to C9-αH; C9-αH is trans to C10-βCH3; C13-βCH3 is trans to C14-αH; C13-βCH3 is cis to C17-β(COCH3); C16-β(CH3) is trans to C17-α[OCO(CH2)5]. The molecules in the crystal are packed at normal van der Waals distances. There are two intermolecular C-H···O interactions: <3.42 Å, C4···O1 (x -1/2, -y + 1/2, -z + 2); C26···O1 (x -1, y + 1, z), 3.41(2) and 3.40(2)Å, respectively.
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ANALYTICAL SCIENCES OCTOBER 2001, VOL. 17 Fig. 1 Molecular structure of the title compound with atom labeling. Thermal ellipsoids are drawn at the 50% probability level. 
